Opinion|Videos|April 7, 2025
Monitoring Tumor Heterogeneity and Detecting Resistance
Experts discuss the tools available to monitor tumor heterogeneity and detect resistance, examining the reliability of current testing methods, differences in molecular testing for newly diagnosed metastatic patients vs those who have progressed, the role of liquid biopsy compared to traditional tissue biopsy, and how these test results inform risk assessment and clinical decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What tools do we currently have to monitor tumor heterogeneity and detect resistance? How reliable are our current testing methods in capturing the complete resistance profile?
- How does molecular testing differ for newly diagnosed metastatic patients vs those who have progressed on prior therapies?
- What role does liquid biopsy play compared to traditional tissue biopsy in detecting heterogeneity?
- How do you incorporate these test results into your risk assessment and clinical decision-making?
Advertisement
Related to this article
The designation covers QTX3034 plus cetuximab with or without FOLFOX; phase 1 data showed a 25% confirmed ORR with the doublet in CRC and PDAC.
MimiVax and Roswell Park announced phase 2b SURVIVE trial results evaluating the SurVaxM vaccine in newly diagnosed glioblastoma.
Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.
The FDA granted fast track designation to MC001 for pancreatic cancer.
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5